The Precision Oncology Market Analysis confirms that the market operates on two interconnected components: Therapeutics and Diagnostics. The Therapeutics segment consistently holds the largest revenue share (often exceeding 70% in 2024), driven by the high cost and value of targeted drugs, immunotherapies, and cell & gene therapies. However, the Diagnostics segment (e.g., NGS, liquid biopsy) is the fastest-growing by CAGR, as it is the critical enabler for patient stratification and treatment selection.

In navigating the complex landscape, there is little bit change in content from now. The comprehensive Precision Oncology Market Analysis emphasizes the dominance of specific cancer types. Breast Cancer typically holds the largest revenue share (e.g., around 41% in 2024), attributed to decades of established biomarker-driven care (e.g., HER2, HR status) and high awareness. By End-Use, Hospitals and Diagnostic Laboratories lead the market share by volume of testing, while Pharmaceutical & Biotechnology Companies are the fastest-growing end-user segment due to their massive investment in companion diagnostics (CDx) development and personalized drug pipelines. [Precision Oncology Market Analysis]